| Q64256782 | A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis |
| Q37552126 | Advances in renal bone disease: osteoporosis and chronic kidney disease |
| Q30870287 | Application of modeling and simulation to a long-term clinical trial: a direct comparison of simulated data and data actually observed in Japanese osteoporosis patients following 3-year ibandronate treatment |
| Q54313739 | Bisphophonates in CKD patients with low bone mineral density. |
| Q33505798 | Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies |
| Q36997750 | Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle |
| Q36162247 | Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis |
| Q37029012 | Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis |
| Q34250632 | Clinician's Guide to Prevention and Treatment of Osteoporosis |
| Q92855151 | Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial |
| Q35858255 | Dose-Effectiveness Relationships Determining the Efficacy of Ibandronate for Management of Osteoporosis: A Meta-Analysis |
| Q41091281 | Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study |
| Q64094819 | Effectiveness of monthly intravenous ibandronate injections in a real-world setting: Subgroup analysis of a postmarketing observational study |
| Q33965657 | Efficacy of ibandronate: a long term confirmation. |
| Q44114890 | Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study |
| Q36056975 | Evidence of sustained vertebral and nonvertebral antifracture efficacy with ibandronate therapy: a systematic review |
| Q53559191 | Higher response with bone mineral density increase with monthly injectable ibandronate 1 mg compared with oral risedronate in the MOVER study. |
| Q82367199 | Ibandronate for prevention and treatment of glucocorticoid-induced osteoporosis in rabbits |
| Q86551275 | Ibandronate in stable renal transplant recipients with low bone mineral density on long-term follow-up |
| Q37354137 | Ibandronate: a review of its use in the management of postmenopausal osteoporosis |
| Q34553500 | Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study |
| Q34645740 | Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice |
| Q34041189 | Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension |
| Q44468289 | Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies |
| Q34018048 | Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis |
| Q36059589 | Medical treatment of osteoporotic vertebral fractures |
| Q54615209 | Monthly oral ibandronate 100 mg is as effective as monthly intravenous ibandronate 1 mg in patients with various pathologies in the MOVEST study. |
| Q37254577 | Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates |
| Q34272000 | Once-monthly risedronate for postmenopausal osteoporosis |
| Q37192994 | Optimizing dosing frequencies for bisphosphonates in the management of postmenopausal osteoporosis: patient considerations |
| Q87167754 | Postoperative Protocol in the Prevention of Fragility Fractures in Patients with Osteoporosis-Related Fractures |
| Q35940958 | Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis |
| Q37417515 | Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. |
| Q57493278 | Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation |
| Q91672148 | Safety and effectiveness of monthly intravenous ibandronate injections in a prospective, postmarketing, and observational study in Japanese patients with osteoporosis |
| Q34486831 | Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report |
| Q91671784 | Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis |
| Q37296051 | The impact of persistence with bisphosphonates on health resource utilization and fracture risk in the UK: a study of patient records from the UK Clinical Practice Research Datalink |
| Q44892769 | The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. |
| Q37765866 | Update on the use of zoledronic acid in the management of osteoporosis |
| Q37339005 | Use of bisphosphonates for the treatment of stress fractures in athletes |